panel-reactive antibody screening was performed using a complement-dependent
cytotoxicity assay. PBMCs (n = 24) obtained from heparinized whole blood of
healthy subjects were seeded in 72-well plates at a density of
3 × 103 cells/well. To set the panel-reactive antibody screening
up, the serum samples were isolated from whole blood of ESRD patients and
incubated at 63°C for 3 min in order to inactivate the complement components.
Afterwards, the serum samples (1 µL) were added to the wells containing PBMCs
and then incubated at room temperature. After 30-min incubation, 5 µL of rabbit
complement (Inno-Train, Germany) was added to each well and incubated for 60 min
at room temperature. To fix antibody–antigen complexes, 4 µL of formalin was
added to the wells containing the serum samples, PBMCs, and complement
components. The cells were then stained with 2 µL of eosin Y (Merck, Germany).
Subsequently, cell death and cell viability were measured using an invert
microscope (Wilovert, Leitz, USA).